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Dietary fibre and probiotics may play a role in the management of diverticular disease. In adults with  
asymptomatic (AS) or symptomatic uncomplicated diverticular disease (SUDD), this systematic review 
aims to synthesize evidence on the efficacy of dietary fibre modifications, with or without the use of 
probiotics, on gastrointestinal function, symptoms, and diverticulitis incidence. Five electronic 
databases were searched for studies until December 2018. The body of evidence was appraised using 
the Cochrane Risk of Bias tool and GRADE. Nine studies were included with mean sample ages ranging 
from 57 to 70 years, and three meta-analyses were performed. Only one study, with high risk of bias, 
measured the effect of dietary fibre on diverticulitis incidence. Dietary fibre supplementation was found 
to improve stool weight (MD: 42g/day, P<0.00001; GRADE level of evidence: low), but had no 
significant effect on gastrointestinal symptoms (SMD:-0.13, P=0.16; GRADE level of evidence: low) 
or stool transit time (MD:-3.70, P=0.32 GRADE level of evidence: low). There was “very low” 
confidence for the body of evidence supporting symbiotics for AS or SUDD. A high dietary fibre intake, 
in line with dietary guidelines, may improve gastrointestinal function and is recommended in patients 
with AS or SUDD. Dietary fibre supplementation should be considered on an individualised basis to 
improve bowel function, while the recommendation for symbiotic supplements requires further well-
designed research. Future studies should also measure impact on the incidence of diverticulitis. 










Diverticulitis is one of the most common and costly gastrointestinal disorders, primarily 
presenting in older adults [1-6]. Diverticulitis is a complication of diverticulosis, a condition 
defined by the presence of colonic diverticula, which are mucosal herniations in the muscle 
layer of the colon wall [7]. Diverticulosis can present itself as asymptomatic (AS) diverticular 
disease or as symptomatic uncomplicated diverticular disease (SUDD). SUDD differs from AS 
in that the herniations are associated with persistent gastrointestinal symptoms (GIS) similar to 
that of irritable bowel syndrome, such as flatulence, pain, faecal urgency, bloating, and altered 
bowel function for at least three months without acute inflammation [8, 9]. Due to the overlap 
in both pathogenesis and symptoms between SUDD and irritable bowel syndrome, 
misdiagnosis is common [10]. Signs of acute inflammation of the diverticula are indicative of 
diverticulitis, which presents with acute, severe GIS including abdominal pain, tenderness, 
fever, and/or altered bowel function [11]. Diverticulitis cases may develop sepsis, pelvic ulcers, 
haemorrhages, and perforations. Often an episode of diverticulitis is the trigger for an accurate 
diagnosis of AS or SUDD, whereas symptoms previously may have been considered to be due 
to irritable bowel syndrome [10]. For this reason, studies with patients diagnosed with AS or 
SUDD often have samples where participants have had one or more episodes of diverticulitis 
in the past. 
Risk factors for diverticular disease include ageing, adiposity, sedentary lifestyles, and 
diet, specifically dietary fibre intake [12-14]. Prospective cohort studies have identified a link 
between overall dietary fibre intake an primary prevention of both diverticulosis and 
diverticulitis, where adults with the highest intakes of dietary fibre had approximately 40% 
decreased relative risk of diagnosis [15-17]. The influence of dietary fibre intake on diverticular 
disease is suggested to be due to its influence on bowel health and function, particularly 








inflammation of the diverticula [18, 19]. Insoluble dietary fibres can act as a prebiotic as they 
may be fermented by gut microbiota to optimise bacterial fatty acid production that reduces 
inflammation and supports the growth of functioning of beneficial gut bacteria to strengthen 
the colonic wall [20-22]. Combining prebiotics with probiotics (beneficial live bacteria) as a 
symbiotic for diverticulitis prevention is of interest, they might counteract the altered 
gastrointestinal microflora associated with the disease to improve functioning of the intestine 
[20].  
Despite the important role dietary fibre has in bowel function, General Practitioners do 
not regularly recommend dietary fibre modifications as a treatment of AS or SUDD, reflecting 
the lack of intervention evidence currently available [23]. Dietary fibre and probiotics have 
been examined for diverticular disease in four systematic reviews previously; in addition to the 
inclusion of more recent published literature, the previous reviews were limited by the 
relatively poor quality of included studies (i.e. lack of randomised blinding and placebo 
control), inadequate specification of probiotic strains, narrow search strategies, and failing to 
examine outcomes related to GIS or bowel function [24-28].  
Therefore, there is currently a gap in the literature regarding the role of dietary fibre on 
AS and SUDD management. In adults with  AS or SUDD, this systematic review aims to 
synthesize evidence on the efficacy of dietary fibre modifications, with or without the use of 
probiotics, on gastrointestinal function, symptoms, and diverticulitis incidence. 
Methods  
This systematic review has been reported according to the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) statement [29]. The full search strategy is 
shown in Online Supplementary Material 1. Briefly, Medline (PubMed), Embase, The 








design from database inception up until 12th December 2018 and were complemented by a 
snowball search of Google Scholar and reference lists of similar review articles.  
Eligibility criteria 
Studies in any language were included if they included adults (≥18 years) with current 
diagnosis of diverticular disease (as older studies do not often specify if participants had AS or 
SUDD), AS, or SUDD, who received dietary or supplemental fibre modifications (either a  
decrease or increase in dietary fibre intake) with or without probiotic administration. Due to 
the unavailability of CT diagnosis in many settings, this was not a requirement for eligibility; 
therefore, participants were considered as having diverticular disease, AS, or SUDD if 
diagnosed by any assessment method. Studies were excluded from this review if a medication 
likely to affect gut functioning (antibiotic, laxative or anti-inflammatory) was co-administered 
as part of the intervention or used as a comparator if the intervention didn’t also use the same 
drug. 
Observational studies, reviews, abstracts, study protocols, and conference papers, or 
those that did not report on any outcome of interest were excluded from this review. Studies 
that assessed primary prevention (diverticular disease development in healthy populations) 
were excluded. Studies which addressed tertiary prevention (acute diverticulitis treatment) 
were excluded and reported elsewhere [30].  Screening of titles, abstracts and full-texts was 
completed by four investigators independently ([FE or MC] and [CD or SM]). 
Outcomes of interest 
To reflect occurrence of acute diverticulitis, the primary outcome of interest was the incidence 
of acute diverticulitis, defined as the presence of acute inflammation in diverticula with or 








(outpatient visits, hospitalisation, health care costs), GIS, bowel habits, complications 
(treatment failure of diverticulitis, abscess, perforation or haemorrhaging, requiring drainage 
or surgery), and participant quality of life.  
Review of study quality and confidence in the body of evidence 
Using the Cochrane risk of bias tool, study quality was assessed independently by three 
researchers (CD and [MC or SM]); and reviewed for accuracy by a third researcher (MC or 
SM) [31]. Two authors independently assessed the certainty in the body of evidence and 
developed recommendations for populations using GRADE [32], as outlined by the GRADE 
Handbook [33] and implemented using the software GRADEpro GDT [GRADEpro Guideline 
Development Tool, McMaster University, 2015; developed by Evidence Prime, Inc].  
Data extraction and meta-analysis 
Outcome scores and mean change from baseline for both groups were extracted. All data 
extraction was conducted by one researcher (CD or MC), and all extracted data were checked 
for accuracy by a senior researcher (SM). Where two or more studies had clinical homogeneity 
and reported data in enough detail, data were pooled by meta-analysis using Review Manager 
[Review Manager 5, Version 5.3, 2014, Cochrane Informatics & Knowledge Management 
Department] using random effects models. The pooled categorical outcomes were reported 
using risk ratio with 95% confidence intervals, using the Mantel-Haenszel test. Pooled 
continuous outcomes were reported as mean differences (MD), where the same outcome 
assessment tool and scale was used. Where standard deviations weren’t reported by the original 
study, they were calculated by Review Manager using the outcome, participant number and P-
values (P=0.05 used if reported as not significant). Statistical significance for meta-analyses 









Search results and study quality 
The search strategy located 8,326 records and a further 13 studies were identified by snowball 
searching (Figure 1). After title and abstract screening, the full-text of 141 studies were 
considered and nine studies published between 1972 and 2012 were included (Table 1). Four 
studies (with a total of five intervention arms) were included in three meta-analyses [34-37].  
The Cochrane risk of bias tool indicated most studies had either high or unclear risk of 
bias for most domains (Figure 2; justifications in Online Supplementary Material 2). One of 
the most common causes of risk of bias across the body of evidence was the lack of objective 
and/or validated subjective measures in regards to GIS; and a lack of blinding which is 
particularly problematic given the susceptibility of self-perceived GIS to the placebo effect 
[38]. Other bias of major concern is the large number of studies which were funded by 
pharmaceutical and/or supplement companies, that had undescribed involvement in the studies, 
combined with incomplete data reporting which tended to favour the product investigated. 
Furthermore, most studies either did not use randomisation or concealed allocation, or it was 
not described with sufficient detail to determine if it was well implemented. Due to the small 
number of included studies for each outcome combined in meta-analyses, publication bias 
could not be evaluated. 
Characteristics of included studies 
Six studies were randomised controlled trials (comprising n=3 RCT, n=3 cross-over RCTs) 
and the remaining three were uncontrolled pre-test post-test trials. One RCT [36] and one cross-
over RCT [39] both had two eligible intervention arms (i.e. 3-arm RCT designs). Sample sizes 
varied from n=10 to n=76 participants and the majority (n=6) were from the United Kingdom. 








years, excepting one sub-sample aged 57 years [35] and one study which did not report 
participant age [40]. Therefore, the participants included in this review were considered to meet 
the United Nations criteria for older adults (≥60 years) [41]. The samples in all studies were 
reported to be diagnosed with SUDD, except for two studies which didn’t specify the type of 
diverticular disease in their samples [34, 35]. 
 
Only two studies, both of which used symbiotic interventions, standardised the background 
diet in participants [39, 42]. Of the seven remaining RCTs which modified total dietary fibre 
intake via supplemental dietary fibre interventions, five did not describe or control the 
background diet in any way [34, 35, 37, 43, 44], and the remaining two only controlled the 
background diet by recommending “habitual intake” to participants. However, the cross-over 
design may control for the impact of background diet between groups for three of these studies 
[34-36]. Only the intervention described by Painter et al [43] modified dietary intake through 
dietary sources; however, the amount of dietary fibre from the diet was not measured, and the 
study also provided dietary fibre supplements. 
 
Of the five studies (n=6 intervention groups) which provided a dietary fibre intervention 
without probiotics, four provided wheat brain supplementation (6.7 to 45g/day; 3 to 22 months 
duration) [36, 37, 40, 43], three provided ispaghula supplementation (7 to 12g/day; 1 to 4 
months duration [34, 36, 44], and one provided methylcellulose (1g, 3 months duration) [35]. 
The two remaining studies (n=3 intervention groups) provided symbiotics, Lactobacillus (5-
billion to 12-billion colony forming units (CFUs)) was provided in a combination with 
oligosaccharides (prebiotic) for 6-months. [39, 42] 
Dietary fibre administration in the prevention of diverticulitis and associated outcomes in 








There were seven intervention studies with eight intervention arms (published 1972 – 1992) 
which evaluated the efficacy of 1-month to 3-years dietary fibre supplementation [34-37, 44-
46] (Table 1). One of these studies had two intervention groups [36] and three had no 
comparator group [44-46].  
Dietary fibre administration in the prevention of diverticulitis 
The effect of dietary fibre on diverticulitis prevention was assessed by Painter et al [46] with 
no comparator group which administered an unspecified high dietary fibre diet with two 
teaspoons of bran supplementation three times per day [46]. Painter et al [46] found 2% of the 
study population developed diverticulitis over a 39 month follow up period. Due to lack of 
additional studies, data could not be pooled and GRADE assessment was not completed. 
Dietary fibre administration in the improvement of gastrointestinal symptoms 
The three studies which implemented a pre-test post-test design with no comparator groups 
found improvements in GIS and bowel habits from baseline with either ispaghula husk 
supplementation (7g daily) or high fibre diets and/or wheat bran supplementation (3-45g daily) 
[44-46] (Table 1). Three studies which compared dietary fibre supplementation versus placebo 
on GIS (evaluated by a range of un-validated tools) could be pooled [35-37], finding 
insufficient evidence to reject the null hypothesis (SMD: -0.13 [95%: -0.31 to 0.05]; P=0.16; 
I2: 33%; n= 4 intervention groups; n= 161 participants) [35-37]. There was “low” confidence 
in the body of evidence that there is no effect of dietary fibre supplementation on GIS.  
Dietary fibre administration in the improvement of bowel function 
Two meta-analyses could be performed to examine the impact of dietary fibre on bowel 
function. A meta-analysis of three intervention groups found that dietary fibre significantly 








intervention groups [2 ispaghula husk; n=1 bran]; n=2 studies, n=134 participants) [34, 36]; 
however, heterogeneity was substantial at I2: 65%. When including only ispaghula husk, there 
was a large effect (MD: 42g/day [95%CI: 26-57g]) with no heterogeneity (Figure 3); however, 
the analyses was heavily weighted to only one study. The quality of the body of evidence 
(GRADE assessment) that ispaghula husk increases stool weight indicates there is “low” 
confidence the estimated effect size is close to the true effect in this patient population (Online 
Supplementary Material 3).   
Meta-analysis of two studies reported there was insufficient evidence to reject the null 
hypothesis that dietary fibre impacts upon stool transit time (MD: -3.70 [95%CI: -11.06-3.65]; 
P=0.32; I2: 0%; n=3 interventions groups; n= 134 participants) [34, 36]. There was “low” 
confidence in the body of evidence for the effect of dietary fibre on stool transit time, 
acknowledging a spurious confounding effect of the initial stool transit time on the pooled 
effect size. A large contributor to the low confidence in the body of evidence for these outcomes 
is due to risk of bias and the small sample sizes in the included studies (Online Supplementary 
Material 3).  
Other bowel function-related outcomes reported by studies comparing dietary fibre 
with placebo, but not included in meta-analysis due to lack of consistent data reporting, are 
described in Table 1; these revealed dietary fibre supplementation improved bowel habits such 
as stool consistency and stool frequency. 
Dietary fibre administration on other outcomes of interest 
Only two studies, which had no comparator groups, reported assessment of health 
service use, meaning data could not be pooled and GRADE assessment was not considered. 
Painter et al [46] reported 5% hospital admissions over a 39- month follow up period and 








over an 8- month follow up period. No studies were identified to evaluate the effect of dietary 
fibre intake on patient quality of life or complications. 
 
Symbiotic supplementation in the prevention of diverticulitis and associated outcomes in 
populations with asymptomatic or symptomatic uncomplicated diverticular disease 
There were two studies (published 2011 and 2012) with three intervention groups which 
compared a symbiotic supplement against a usual care (i.e. no intervention), where both groups 
were also advised to follow a high dietary fibre diet (Table 2) [39, 42]. All three interventions 
used Lactobacillus as the probiotic, with dosages ranging from 5-billion colony forming units 
(CFU) to 12-billion CFUs. The prebiotic agents included in the symbiotic preparations were 
either 750mg oligosaccharides alone or 700mg oligosaccharides combined with 1240mg 
arabinogalactan. Symbiotic supplements also contained b-group vitamins or glutamine.  
Both studies reported zero incidence of acute diverticulitis across all groups over a six-
month follow up (no incidence precluding meta-analysis). The symbiotic supplementation in 
all interventions reported improvements in GIS. Those assigned a higher dose of probiotic (12-
billion CFUs) did not benefit from any additional GIS relief compared to those prescribed a 
lower dose. The studies failed to report and represent adequate data for the comparator group 
preventing meta-analysis of GIS, and groups were not compared statistically in any study. 
GRADE assessment revealed there is “very low” confidence that the reported effect sizes 
represent the true effect of symbiotic supplementation on GIS in patients with AS or SUDD. 
This is largely due to a small number of studies examining this outcome, significant risk of 









In older adults with AS or SUDD, existing guidelines recommend a high fibre diet for the long-
term primary prevention of diverticulitis based upon expert opinion and observational cohort 
studies [47-50]. These associations have not yet been sufficiently addressed by intervention 
studies, highlighting the need for renewed focus in this area [22]. This review identified seven 
studies which have explored this dietary management strategy, where only one study, which 
had a high risk of bias, no comparator group, and was published over 40 years ago, measured 
the effect on diverticulitis incidence [46]. Therefore, the effect of a high dietary fibre intake on 
the prevention of diverticulitis in those with AS or SUDD is unknown.  
There was some evidence that GIS improve with high dietary fibre intake, although the 
range of un-validated tools used to measure this outcome makes it difficult to determine 
whether the result was reliable, reflected by the “low” GRADE assessment for this outcome. 
Although ispaghula husk supplementation was found to have a large significant effect on 
increasing daily stool weight, improvement in this outcome alone will not contribute 
significantly to improved symptomatic management of the condition and is considered 
beneficial for this patient group from a theoretical perspective only, as stool weight is 
hypothesised to decrease contact of faecal matter with the colon walls. In addition, there is 
good evidence that dietary fibres from diverse sources increase stool weight to varying degrees 
[51]. This could explain the heterogeneity seen by including wheat bran with ispaghula husk 
in the meta-analysis. Therefore, although heterogeneity was improved by removing wheat bran 
during sensitivity analysis, the small number of included studies and the heavy weighting for 
one study in the meta-analysis prevents the recommendation of ispaghula husk over other 
forms of dietary fibre which have shown to have beneficial effects in other patient groups [51]. 
Additionally, one study [35] included in the meta-analyses for GIS did not report if their sample 









The absence of significant change in stool transit time may be confounded by the 
spurious effect of the baseline transit time as it appears that those with slow transit times 
quickened, and vice versa, meaning there is likely some normalising of stool transit times for 
those with initial short or long transit times. The lack of effect on stool transit time for the 
whole sample may also be confounded by the type of dietary fibre, where soluble dietary fibres 
(such as ispaghula husk) are known to increase transit time, while insoluble dietary fibre types 
(such as bran) decrease transit time [52]. Further research comparing different dietary fibre 
types in patients with AS or SUDD is warranted, due to each fibre having a unique impact upon 
stool mass and transit time due to its unique particle size, prebiotic capacity, and chemical 
composition [51]. 
Conclusions cannot be drawn regarding the impact of symbiotic supplementation on 
either risk of acute diverticulitis nor its impact on GIS due to poor study quality which prevents 
comparison of the intervention group to the control groups. Therefore, although symbiotic 
administration appears safe and may be beneficial, currently there is “very low” confidence in 
the body of evidence for symbiotic supplementation for the prevention of diverticulitis.  
Implications for practice 
Therefore, this review supports a high dietary fibre diet for older adults with AS or 
SUDD, with consideration given to ispaghula husk supplementation on an individualised basis. 
This aligns with dietary guidelines, which recommend a high dietary fibre intake, where 
supplementation is considered if the nutrient target cannot be met by foods alone [53]. Due to 
limitations in the quality of the evidence, it should be recognised that these recommendations 
may change with the availability of new high-quality intervention studies. 








The body of evidence located for each outcome is small and generally of poor quality, 
with most studies having a high risk of bias, warranting future research in the area. Main causes 
of bias should be addressed and avoided in future randomised controlled trials, including 
double-blinding and fully describing the randomisation and allocation process. Objective 
and/or validated outcome measures for GIS are required, and all intervention durations and 
outcome measures should have suitable timeframes of follow-up relevant to each outcome. 
Additionally, background diets should be controlled and fully described, as should adherence 
to the intervention. Future studies with industry and/or pharmaceutical funding should aim to 
ensure independence and transparency through full disclosure of conflicts of interest as well as 
full reporting of results in both control and intervention arms.  
Limitations 
The terminology referring to diverticular disease varied among studies, and it should 
be acknowledged that due to lack of CT diagnosis, it is possible included samples may have 
been misdiagnosed. Findings were limited as multiple studies did not report outcome data in 
full, leading to prevention of meta-analyses for many outcomes, downgrading the quality of 
the evidence. The small sample sizes suggests that the meta-analyses were underpowered. 
Understanding of the effects of interventions was also limited, as few studies reported the 
background diet of participants or adherence to the dietary intervention.  
Conclusions 
Due to a lack of published intervention evidence, conclusions cannot be drawn 
regarding the effect of dietary fibre or prebiotics on risk of acute diverticulitis in older adults 
with AS or SUDD. Although estimated effect sizes are large, there is low confidence in the 
body of evidence that dietary fibre supplementation may improve stool transit time and stool 








regarding the effect of symbiotic supplementation on GIS or bowel function. Overall, for those 
with AS or SUDD, a high dietary fibre intake in accordance with national gender and age 
specific dietary fibre intake guidelines is recommended, and dietary fibre supplementation 
should be considered on an individualised basis. High quality intervention evidence is needed 
to support evidence-based practice for the dietary management of AS and SUDD in older 
adults. 
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Figure 2: Risk of bias summary: review authors' judgements about selection, performance, 




Figure 3: Two to four months of ispaghula husk supplementation significantly increases 
daily stool weight compared with placebo by a mean of 42g/day (95%CI: 26-57g; 
P<0.00001). 
  
Table 1: Study characteristics and outcomes of n=7 studies and n=8 groups of interest examining the effect of dietary fibre in the prevention of 
acute diverticulitis and other outcomes in those with AS or SUDD. 
Study & design Setting & population Group of Interest / 
Intervention group 
Comparator Group Results 















diagnosis: SUDD  
Data collected: not 
specified 
Female: 50% 




Supplement: Bran crispbread 
with dietary fibre 
Dose: 9 per day, providing an 
additional 6.7g dietary fibre 
per day 
Duration: 3-months 
Background diet: No other 
alterations made 
 
Supplement: Placebo wheat 
crispbread with very low 
dietary fibre 
Dose: 9 per day, providing an 
additional 0.6g dietary fibre per 
day 
Duration: 3-months 
Background diet: No other 
alterations made 
 
Gastrointestinal symptoms: At 3-months post-baseline: 
Gastrointestinal symptom score (not validated tool; score range unknown; 
higher indicates worse symptoms):  
IG: μ8.1 (mean change -26.2) vs CG: μ35.1 (mean change -6.9); P<0.002 
between groups. 











n=76 for each group) 
Attrition: 24% (n=58 
for each group) 
Background 
diagnosis: SUDD 
with ≥6 diverticula 
Data collected: not 
specified. 
Female: 62% 
Supplement:  Ispaghula 
(a.k.a. psyllium) powder + 
placebo wheat crispbread 
Dose: 2 sachets of powder + 8 
crispbread per day, providing 
an additional 9.0g dietary 
fibre per day. 
Duration: 4-months. 
Background diet: Habitual 
diet and restricted from 
adding additional fibre 
Supplement: Placebo wheat 
crispbread + placebo wheat 
powder, both with little dietary 
fibre 
Dose: 8 crispbreads and two 2 
sachets of powder per day, 
providing an additional 2.3g 
dietary fibre per day 
Duration: 4-months 
Gastrointestinal symptoms: At 4-months post-baseline:  
Abdominal pain score (scored 0-100; higher indicates worse symptoms): 
IG: μ19.5±18.4; mean change -3.1a (P>0.05 since baseline) vs CG: μ 
17.5±15.6; mean change -5.1a (P>0.05 since baseline); P>0.05 between 
groups. 
Lower bowel symptom score (scored 0-210; higher indicates worse 
symptoms):  
IG: μ41.3±27.4; mean change -6.1a (P>0.05 since baseline) vs CG: 
μ45.0±28.3; mean change -2.4a (P>0.05 since baseline); P>0.05 between 
groups. 








Median age: 64 
(range 43-78 years) 
 Background diet: Habitual diet 
and restricted from adding 
additional fibre 
 
IG: μ8.1±6.7; mean change -1.6a (P>0.05 since baseline) vs CG: μ7.6±7.3; 
mean change -2.1a  (P>0.05 since baseline); P>0.05 between groups. 
Bowel habits: At 4-months post-baseline:  
Daily wet stool weight (n=57 participants per group): 
IG: μ161.0±59.8g (P<0.001 increase since baseline) vs CG: μ118.8± 5.4g 
(P>0.05 since baseline); between groups not assessed; mean changes not 
reported. 
Weekly stool frequency (n=58 participants per group): 
IG: μ11.19±3.4 (P<0.001 increase since baseline) vs CG: μ9.6±2.9 (P>0.05 
since baseline); between groups not assessed; mean changes not reported. 
Stool consistency score (range 1 to 5; 1=very hard to 5=very soft) (n=58 
participants per group): 
IG: μ4.1±0.8 (P<0.001 increase since baseline) vs CG: μ3.6±0.9 (P>0.05 
since baseline); between groups not assessed; mean changes not reported. 
Stool transit time (n=39 participants per group): 
IG: μ46.9±22.9hrs (P>0.05 since baseline) vs CG: μ 49.9±24.4hrs (P>0.05 
since baseline); between groups not assessed; mean changes not reported. 
Supplement: Bran crispbread 
with dietary fibre + placebo 
wheat powder  
Dose: 8 crispbreads + 2 
sachets of powder per day, 
providing an additional 7.0g 
dietary fibre per day. 
Duration: 4-months 
Background diet: Habitual 
diet and restricted from 
adding additional fibre 
 
Supplement: Placebo wheat 
crispbread + placebo wheat 
powder, both with little dietary 
fibre 
Dose: 8 crispbreads and two 2 
sachets of powder per day, 
providing an additional 2.3g 
dietary fibre per day 
Duration: 4-months 
Background diet: 
Habitual diet and restricted 
from adding additional fibre 
Gastrointestinal symptoms: At 4-months post-baseline:  
Abdominal pain score (scored 0-100; higher indicates worse symptoms): 
IG: μ15.2±16.9; mean change -7.4a (P>0.05 since baseline) vs CG: 
μ17.5±15.6; mean change -5.1a (P>0.05 since baseline); P>0.05 between 
groups. 
Lower bowel symptom score (scored 0-210; higher indicates worse 
symptoms):  
IG: μ39.7±27.4; mean change -7.7a (P>0.05 since baseline) vs CG: 
μ45.0±28.3; mean change -2.4a (P>0.05 since baseline); P>0.05 between 
groups. 
General symptom score (scored 0-55; higher indicates worse symptoms): 
IG: μ6.7±5.9; mean change -3.0a (P>0.05 since baseline) vs CG: μ7.6±7.3; 
mean change -2.1a (P>0.05 since baseline); P>0.05 between groups. 
Bowel habits: At 4-months post-baselineb:  








IG: μ136.5±49.9g (P<0.001 increase since baseline) vs CG: μ118.8± 5.4g 
(P>0.05 since baseline); between groups not assessed; mean changes not 
reported. 
Weekly stool frequency (n=58 participants per group): 
IG: μ10.3±3.0 (P<0.001 increase since baseline) vs CG: μ9.6±2.9 (P>0.05 
increase since baseline); between groups not assessed; mean changes not 
reported. 
Stool consistency score (range 1 to 5; 1=very hard to 5=very soft) (n=58 
participants per group):  
IG: μ3.8±0.8 (P<0.001 increase since baseline) vs CG: μ3.6±0.9 (P>0.05 
increase since baseline); between groups not assessed; mean changes not 
reported. 
Stool transit time (n=39 participants per group): 
IG: μ45.3±22.4hrs (P>0.05 increase since baseline) vs CG: μ49.9±24.4hrs 













data not considered 
as results not 
reported sufficiently) 
Attrition: 10% (IG: 




(Non- specific of AS 
or SUDD) 




(bulking agent)  
Dose: 2x500g tablets per day 
(1g per day) 
Duration: 3-months 
Background diet: Not 
described  
 
Supplement: Placebo maize 
starch tablets (non-bulking 
starch). 
Dose: 2x500g tablets per day 
(1g per day) 
Duration: 3-months 
Background diet: Not 
described  
 
Gastrointestinal symptoms: at 3-months post-baseline: 
Symptom score (ranging 0 – 50; higher indicates worse symptoms): 
IG: μ13.0±4.2; mean change -6.0 (P<0.01 decrease since baseline) vs CG: 









Mean age: 57- 64 
(range 32-85 years) 











Attrition: 10% (n=9 





(Non-specific of AS 
or SUDD) 
Data collected: not 
specified. 
Female: 67% 
Median age: 68 
(range: 62-77 years) 
Supplement: Vi-Siblin 
(granulate of dried ispaghula 
husk)  
Dose: 2x6g containers of 
powder per day (12g per day) 
Duration: 2-months 






Supplement: Placebo lactose   
Dose: 2x6g in an unknown 
form per day (12g per day) 
Duration: 2-months 




Gastrointestinal symptoms: at 2-months post-treatment initiation: 
Flatus (incidence): 
IG: μ0 vs CG: μ2; P>0.05 between groups; means change not reported. 
Dyspepsia (incidence): 
IG: μ0 vs CG: μ2; P>0.05 between groups; means change not reported. 
Bowel habits: At 1-month post-baseline:  
Stool transit time: 
IG: μ72 (range 51-102hrs) vs CG: μ63 (range 30-99hrs); P>0.05between 
groups; means change not reported. 
Diarrhoea (incidence): 
IG: 0 vs CG: 1; P>0.05 between groups; means change not reported. 
Constipation (incidence): 
IG: 1 vs CG: 3; P>0.05 between groups; means change not reported. 
Stool consistency (incidence of hard stools): 
IG: 1 vs CG: 6; P<0.05 between groups; means change not reported. 
Stool weight: 
IG: μ121g vs CG: μ109; P>0.05 between groups; means change not reported. 
Stool frequency: 
IG: μ0.98 movements per day vs CG: μ1.02 movements per day; P>0.05 
between groups; means change not reported. 











Attrition: 0%  
Background 
diagnosis: SUDD 
Data collected: not 
specified. 
Supplement: Wheat bran  
Dose: 3 heaped tablespoons 
(approx. 24g) per day 
Duration: minimum 6-
months; mean 8-months. 
Background diet: Instructed 
to maintain habitual diet 
 
No comparator group. Gastrointestinal symptoms: at μ8-months post-baseline: 
Pain severity (number of patients experienced a decrease of those with 
symptom at baseline): 
91% decreased in right iliac fossa pain; 100% decreased left iliac fossa pain; 
96% decreased generalised pain; 100% decreased colic pain. 
Dyspeptic symptoms severity (number of patients experienced a decrease of 













age: not specified. 
 86% decreased in nausea; 85% decreased in flatulence; 78% decreased in 
distension; 79% decreased in wind; 100% decreased in vomiting. 
None evaluated statistically. 
Bowel habits: at μ8-months post-baseline:  
Bowel symptoms severity (number of patients experienced a decrease of those 
with symptom at baseline): 
92% decreased straining; 80% decreased pain on defecation; 97% decreased 
hard or loose bowel motion; not evaluated statistically. 
Wet stool weight: 
μ89; mean change 23 (P<0.0002 increase since baseline) 
Stool frequency: 
n=0 had motion every ≥3days (n=5 at baseline); n=6 had motion ≥3 per day 
(n=18 at baseline); not evaluated statistically. 
Stool consistency (incidence of hard stools): 
n=2 had hard to very stools (n=25 at baseline); n=1 had liquid stool (n=7 at 
baseline); not evaluated statistically. 
Stool transit time: 
Baseline rapid transit time group: μ45hrs; mean change 24hrs.  
Baseline medium transit time group: μ49hrs; mean change 2hrs. 
Baseline slow transit time group: μ48hrs; mean change not reported (P<0.006 
decreased since baseline). 
Health service use: 
Hospitalisation incidence: 
n=0  













Data collected: not 
specified. 
Female: 40% 
Supplement: Ispaghula husk 
Dose: 2x3.5g sachet (7g total 
per day) 
Duration: 1-month 




No comparator group. Gastrointestinal symptoms: at 1-month post-baseline: 
Abdominal pain 
70% decreased in abdominal pain; data not reported. 
Bowel habits: At 1-month post-baseline:  
Stool transit time: 
IG: median 23.7hrs (range: 18.8-35.5); median change -8.8hrs (range -42.6-












Median age: 63-70 
(range 50-79 years) 
  
Painter et al 



















Mean age: 60 (range 
36-82 years) 
Intervention: High fibre, low-
sugar diet + bran 
supplementation 
Dose: Grams per day of high 
fibre diet not described; bran 
dosage varied from 3-45g 
depending on patient 
response) 
Duration: 3-years and 3-
months (mean 22 months 
adherence to bran 
supplementation) 
Background diet: N/A 
No control group First diagnosis of diverticulitis: At 3-years and 3-months follow-up: 
1/62 
Gastrointestinal symptoms: at 1-month post-baseline: 
Complaint of symptom 
87% decrease in symptoms. 
Bowel habits: At 3-years and 3-months follow-up: 
Stool frequency: 
0/62 movement <1 per day (28/62 at baseline) 




SUDD, Symptomatic uncomplicated diverticular disease; MA, Meta-analysis; μ, mean; P, Probability value; UK, United Kingdom; IG, 
Group of interest/intervention group; CG, control group; RCT, Randomised controlled trial; BD, twice daily 
a. Mean change was not reported in the study but calculated by subtracting the final outcome score from the baseline score 
b. Unclear if data presented is mean change or the outcome result. The table describes the value as “objective changes”; however, baseline 
values are not reported. The scores and results appear to be more likely to be the final result despite being described as a change. 
c. Sample includes two patients who had acute diverticulitis before taking bran but as they both had a normal white cell count and 









Table 2: Study characteristics and outcomes of n=2 studies and n=3 groups of interest examining the effect of symbiotics on the prevention of 
acute diverticulitis and other outcomes in those with AS or SUDD. 
Study & design Setting & population Group of Interest / Intervention 
group 
Comparator Group Results 






Included in MA: 
No.  
Italy 
n=50 (n=18 2/day probiotic 
group; n=16 4/day probiotic 
group; n=16 control group) 
Attrition: 14% (n=15 2/day 
probiotic group; n=13 4/day 
probiotic group; n=15 control 
group) 
Background diagnosis: SUDD 
Data collected: not specified. 
Female: 64% 
Mean age: 65±8.1 
 
Symbiotic: 2.5g Lactobacillus 
paracasei sub. Paracasei 
F19(12x109 CFU) mixed with 
750g gluco-oligosaccarides, and B-
group vitamins. 
Dose: 2x preparations per day (5g 
probiotic; 1.5g prebiotic). 
Duration: first 14-days per month 
for 6-months 
Background diet: Recommended 
high-fibre (>30g dietary fibre) and 
1.5L water. Diet sheet given. 






(>30g dietary fibre) and 
1.5L water. Diet sheet given. 
 
First diagnosis of diverticulitis: At 6-months post-baseline:  
IG:0/18 vs CG: 0/16. Not compared between groups.  
Gastrointestinal symptoms: At 6-months post-baseline:  
Abdominal pain (visual analogue scale; scored 0-10; higher 
score indicates worse symptoms): 
IG: μ1.9±2.2; mean change -1.8a (P=0.23 since baseline) vs 
CG: data not reported; (P>0.05 since baseline); not 
compared between groups. 
Bloating (visual analogue scale; scored 0-10; higher score 
indicates worse symptoms): 
IG: μ2.3±2.0; mean change -2a (P<0.05 since baseline) vs 
CG: data not reported (P>0.05 since baseline); not compared 
between groups. 
  
Symbiotic: 2.5g Lactobacillus 
paracasei sub. Paracasei F19 
(12x109 CFU) mixed with 750g 
gluco-oligosaccarides, and B-group 
vitamins. 
Dose: 4x preparations per day (10g 
probiotic; 3g prebiotic). 
Duration: first 14-days per month 
for 6-months 






(>30g dietary fibre) and 
1.5L water. Diet sheet given. 
 
First diagnosis of diverticulitis: At 6-months post-baseline:  
IG:0/16 vs CG: 0/16. Not compared between groups. 
Gastrointestinal symptoms: At 6-months post-baseline:  
Short-lasting abdominal pain (visual analogue scale; scored 
0-10; higher score indicates worse symptoms): 
IG: μ0.6±0.9; mean change -1.6a (P>0.05 since baseline) vs 
CG: data not reported; not compared between groups. 
Bloating (visual analogue scale; scored 0-10; higher score 








Background diet: Recommended 
high-fibre (>30g dietary fibre) and 
1.5L water. Diet sheet given. 
IG: μ1.8±2.1; mean change -2.1a (P<0.05 since baseline) vs 
CG: data not reported (P>0.05 since baseline); not compared 
between groups. 
 





Included in MA: 
No. 
Italy 
n=52 (n=30 IG; n=22 control 
group) 
Attrition: 15% (n=23 IG; n=21 
CG) 
Background diagnosis: SUDD 
Data collected: not specified. 
Female: 67% 
Mean age: 66.3±9.5 
 
 
Symbiotic: 7g Lactobacillus 
paracasei B12060 (5x109 CFU) 
mixed with 700 g xylo-
oligosaccarides, 500mg glutamine 
and 1243mg arabinoalactone. 
Dose: 1x preparations per day, 
dissolved in water. 
Duration: 6-months 
Background diet: Recommended 
high-fibre (>30g dietary fibre) and 
1.5L water. Diet sheet and 
counselling given. 
 






(>30g dietary fibre) and 
1.5L water. Diet sheet given. 
 
First diagnosis of diverticulitis: At 6-months post-baseline:  
IG:0/30 vs CG: 0/22. Not compared between groups. 
Gastrointestinal symptoms: At 6-months post-baseline:  
Short-lasting abdominal pain (visual analogue scale; scored 
0-10; higher score indicates worse symptoms): 
IG: μ2.2±0.8; mean change -2.4a (P=0.02 since baseline) vs 
CG: μ2.0±1.9; mean change -2.6a (P=0.03 since baseline); 
not compared between groups. 
Prolonged abdominal pain (visual analogue scale; scored 0-
10; higher score indicates worse symptoms): 
IG: μ4.5±2.1; mean change -2.0a (P=0.052 since baseline) vs 
CG: μ5.5±3.5; mean change 1.0a (P>0.05 since baseline); 
not compared between groups. 
Bloating (visual analogue scale; scored 0-10; higher score 
indicates worse symptoms): 
IG: μ3.0±1.7; mean change -2.3a (P=0.005 since baseline) vs 
CG: μ2.3±1.9; mean change -3.0a (P=0.006 since baseline); 
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Online Supplementary Material 1: Search strategy implemented across five electronic databases  
PubMed and The Cochrane Library was searched 11 December 2018 for the following keywords (all 
text) and MeSH terms:  
1. dietary fiber [MeSH term] OR dietary carbohydrates [MeSH term] OR fibre, dietary [MeSH 
term] OR prebiotics [MeSH term] OR fasting [MeSH term] OR food deprivation [MeSH 
term] OR diet [MeSH term] 
2. fibre [keyword] OR fiber [keyword] OR carbohydrate* [keyword] OR resistant starch* 
[keyword] OR diet [keyword] OR dietary [keyword] OR “diet therapy” [keyword] OR 
“dietary therapy” OR “dietary management” [keyword] OR nutrition* management OR 
nutrition* therapy  [keyword] OR “ low residu* [keyword] OR roughag* [keyword] OR bran 
[keyword] OR “bowel rest” [keyword] OR “nil by mouth” [keyword] OR nbm [keyword] OR 
“nil per os” [keyword] OR “nothing per os”[keyword] OR fasting [keyword] OR “food 
deprivation” [keyword] OR starvation [keyword] OR prebiotic* [keyword] OR “diet 
restriction” [keyword] OR “conservative treatment” [keyword] OR “conservative therapy” 
[keyword] OR “conservative management” [keyword] 
3. 1 OR 2 
4. diverticulitis [MeSH term] OR diverticulum [meSH term] OR diverticulosis, colonic [MeSH 
term] OR diverticulum, colon [MeSH term] 
5. divertic* [keyword]  
6. 4 OR 5 
7. 3 AND 6  
 
CINAHL(via Ebscohost)  was searched 11 December 2018 using the following keywords and 
CINAHL Headings: 
1. dietary fiber[exp][CINAHL term] OR dietary carbohydrates[exp][CINAHL term] OR 
prebiotics[exp] [CINAHL term] OR fasting[exp] [CINAHL term] OR restricted diet 
[exp][CINAHL term] OR diet[exp][CINAHL term]  
2. fibre [keyword] OR fiber [keyword] OR carbohydrate* [keyword] OR “resistant starch*” 
[keyword] OR diet [keyword] OR dietary [keyword] OR “dietary therapy” OR “dietary 
management” [keyword] OR nutrition* management[keyword] nutrition* therapy  [keyword]  
OR“low residue” [keyword] OR roughage* [keyword] OR bran [keyword] OR “bowel rest” 
[keyword] OR “nil by mouth” [keyword] OR nbm [keyword] OR “nil per os” OR “nothing 
per os”[keyword]  OR restricted diet [keyword] OR fasting [keyword] OR “food deprivation” 
[keyword] OR starvation [keyword]  OR prebiotic* [keyword] OR “conservative treatment” 
[keyword] OR “conservative therapy” [keyword] OR conservative management” [keyword] 
3. 1 OR 2 
4. Diverticulitis[exp][CINAHL term] OR diverticulum[exp] [CINAHL term] OR diverticulum, 
colon[exp] [CINAHL term] 
5. divertic* [keyword]  
6. 4 OR 5 
7. 3 AND 6  
 
Embase was searched 11 December 2018 using the following search terms:  
1. dietary fiber [exp][Emtree term] OR carbohydrate diet[exp][Emtree term] OR prebiotic 
agent[exp][Emtree term] OR diet restriction[exp][Emtree term] or food 
deprivation[exp][Emtree term] OR roughage[exp][Emtree Term] OR bran[exp][Emtree term] 
OR conservative treatment[exp][Emtree term] OR diet [exp][Emtree term] 
2. fibre [keyword] OR fiber [keyword] OR carbohydrate*[keyword] OR “resistant starch*” 
[keyword] OR diet [keyword] OR dietary [keyword] OR “dietary therapy” [keyword] OR 
“dietary management” [keyword] OR nutrition* management [keyword] nutrition* therapy  
[keyword]  OR “low residue” [keyword] OR “bowel rest” [keyword] OR “prebiotic agent” 
[keyword] OR“nil by mouth” [keyword] OR nbm [keyword] OR “nil per os” [keyword] OR 
“nothing per os”[keyword]  OR diet restriction [keyword] OR roughage* OR bran [keyword] 
OR fasting [keyword] OR “food deprivation” [keyword] OR starvation [keyword]  OR 
prebiotic* [keyword] OR “conservative treatment” [keyword] OR “conservative therapy” 
[keyword] OR conservative management” [keyword] 
3. 1 OR 2 
4. diverticulitis [exp][Emtree term] OR diverticulosis [exp][Emtree term] OR colon 
diverticulosis [Emtree term]  
5. divertic* [keyword]  
6. 4 OR 5 
7. 3 AND 6  
 
Web of science was searched 11 December 2018 using the following keywords:  
1. dietary fiber OR dietary carbohydrates OR fibre, dietary OR prebiotics OR fasting OR food 
deprivation  
2. fibre OR fiber OR carbohydrate* OR “resistant starch*” OR diet OR dietary OR “dietary 
management” OR “nutritional management’ OR “low residue” OR roughage* OR bran OR 
“bowel rest” OR “nil by mouth” OR nbm OR “nil per os” OR “nothing per os” OR fasting 
OR “food deprivation” OR starvation OR prebiotic* OR “diet restriction” OR “conservative 
treatment” OR “conservative therapy” OR conservative management”  
3. 1 OR 2 
4. diverticulitis OR diverticulum OR diverticulosis, colonic OR diverticulum, colon  
5. divertic*  
6. 4 OR 5 
7. 3 AND 6  
 
 
Online Supplementary Material 2: GRADE Evidence Table for the evaluation of interventions to manage diverticular disease 
Question: Dietary fibre supplements compared to placebo or no intervention for managing diverticular disease  
Setting: Patients with diagnosed diverticular disease (diverticula present in colon)  
Quality assessment № of patients Effect 
























not serious  not serious  serious b none  83  78  SMD 0.13 SD 
lower 




Bowel habits: stool weight (assessed with: grams) 








66  66  MD 42 grams 
higher 




Bowel habits: transit time (assessed with: hours) 











while no effect 
was observed  
87  48  MD 3.7 hours 
lower 
(11.06 lower to 
3.65 higher)  
⨁⨁◯◯ 
LOW 
CI: Confidence interval; SMD: Standardised mean difference; MD: Mean difference 
a. As assessed by the Cochrane Risk of Bias Tool (Figure 1; Online Supplementary Material 1)  
b. The confidence interval is substantial  
c. Although the confidence intervals are not wide; there is only a small number of participants which is largely made up of cross-over trial participants. This leads 
to decreased confidence that there is no substantial imprecision. 
  
Question: Symbiotic supplementation compared to no intervention for diverticular disease   
Setting: Patients with diverticular disease (diverticula in the colon)   
Quality assessment № of patients Effect 


















Gastrointestinal symptoms (assessed with: Symptom rating scales (not validated)) 





not serious  not serious  very serious 
c 





VERY LOW  
CI: Confidence interval 
a. One RCT, one cluster-RCT and one randomised intervention study  
b. Assessed according to the Cochrane Risk of Bias tool (Online Supplementary Material 1)  
c. Although not pooled; measures of precision are large in individually reported outcomes. The studies also have small sample sizes further decreasing confidence 
in the precision of the reported effect sizes. 
 
 
